Carl Schaper

3.1k total citations · 1 hit paper
27 papers, 1.7k citations indexed

About

Carl Schaper is a scholar working on Cancer Research, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Carl Schaper has authored 27 papers receiving a total of 1.7k indexed citations (citations by other indexed papers that have themselves been cited), including 20 papers in Cancer Research, 12 papers in Oncology and 10 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Carl Schaper's work include Breast Cancer Treatment Studies (18 papers), Advanced Breast Cancer Therapies (10 papers) and Estrogen and related hormone effects (9 papers). Carl Schaper is often cited by papers focused on Breast Cancer Treatment Studies (18 papers), Advanced Breast Cancer Therapies (10 papers) and Estrogen and related hormone effects (9 papers). Carl Schaper collaborates with scholars based in United States, Austria and Denmark. Carl Schaper's co-authors include Sean Ferree, James J. Storhoff, Ivana Šestak, Elena López‐Knowles, J. Wayne Cowens, Mitch Dowsett, Jack Cuzick, Torsten O. Nielsen, Anita K. Dunbier and Michael Gnant and has published in prestigious journals such as Journal of Clinical Oncology, Cancer Research and Clinical Cancer Research.

In The Last Decade

Carl Schaper

27 papers receiving 1.6k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Comparison of PAM50 Risk of Recurrence Score With Oncotype DX and IHC4 for Predicting Risk of Distant Recurrence After Endocrine Therapy

2013 436 citations Mitch Dowsett, Ivana Šestak et al. Journal of Clinical Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Carl Schaper United States	13	1.1k	749	493	339	304	27	1.7k
Yongli Shuai United States	27	647 0.6×	1.3k 1.8×	814 1.7×	521 1.5×	250 0.8×	48	2.7k
Iain Beehuat Tan Singapore	20	748 0.7×	878 1.2×	1.2k 2.4×	408 1.2×	132 0.4×	72	2.2k
Udo Rudloff United States	23	419 0.4×	787 1.1×	561 1.1×	592 1.7×	127 0.4×	75	2.1k
Thierry Petit France	24	718 0.6×	1.3k 1.8×	542 1.1×	316 0.9×	114 0.4×	133	2.2k
Robyn Temple‐Smolkin United States	13	717 0.6×	519 0.7×	406 0.8×	280 0.8×	304 1.0×	22	1.4k
W. P. Peters United States	22	521 0.5×	1.1k 1.4×	315 0.6×	254 0.7×	154 0.5×	59	1.9k
Marbin Pineda United States	22	445 0.4×	396 0.5×	965 2.0×	328 1.0×	209 0.7×	31	1.7k
Milan Radovich United States	25	704 0.6×	1.0k 1.4×	992 2.0×	362 1.1×	232 0.8×	95	2.1k
H. D. Saeger Germany	22	445 0.4×	1.1k 1.4×	815 1.7×	341 1.0×	146 0.5×	63	2.2k
Jane Robertson United Kingdom	22	283 0.3×	1.3k 1.7×	816 1.7×	510 1.5×	210 0.7×	57	2.0k

Countries citing papers authored by Carl Schaper

Since Specialization

Citations

This map shows the geographic impact of Carl Schaper's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Carl Schaper with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Carl Schaper more than expected).

Fields of papers citing papers by Carl Schaper

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Carl Schaper. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Carl Schaper. The network helps show where Carl Schaper may publish in the future.

Co-authorship network of co-authors of Carl Schaper

This figure shows the co-authorship network connecting the top 25 collaborators of Carl Schaper. A scholar is included among the top collaborators of Carl Schaper based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Carl Schaper. Carl Schaper is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Fitzal, Florian, Martin Filipits, Christian Fesl, et al.. (2021). PAM-50 predicts local recurrence after breast cancer surgery in postmenopausal patients with ER+/HER2– disease: results from 1204 patients in the randomized ABCSG-8 trial. British journal of surgery. 108(3). 308–314. 18 indexed citations

Church, S., Irena Pekker, Naeem Dowidar, et al.. (2018). Validating critical analytical variables of a multiplexed gene expression assay measuring tumor inflammation designed to predict response to anti-PD1 therapy.. Journal of Clinical Oncology. 36(5_suppl). 203–203. 2 indexed citations

Lænkholm, Anne‐Vibeke, Maj‐Britt Jensen, Jens Ole Eriksen, et al.. (2018). PAM50 Risk of Recurrence Score Predicts 10-Year Distant Recurrence in a Comprehensive Danish Cohort of Postmenopausal Women Allocated to 5 Years of Endocrine Therapy for Hormone Receptor–Positive Early Breast Cancer. Journal of Clinical Oncology. 36(8). 735–740. 102 indexed citations

Eriksen, Jens Ole, Anne‐Vibeke Lænkholm, Ann Knoop, et al.. (2016). Abstract P2-08-10: Validation of prediction of local recurrence (LR) by Prosigna® (PAM50) in a Danish breast cancer cooperative group (DBCG) cohort of hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated to 5yr of endocrine therapy (ET). Cancer Research. 76(4_Supplement). P2–8. 2 indexed citations

Santonja, Ángela, Nuria Ribelles, Pedro Sánchez‐Rovira, et al.. (2016). Abstract P3-07-14: Prosigna® intrinsic subtyping predicts response to neoadjuvant combination therapy in study that includes herceptin within HER2+ (IHC) patients. Cancer Research. 76(4_Supplement). P3–7. 1 indexed citations

Prat, Aleix, Patricia Galván, Begoña Jiménez, et al.. (2015). Prediction of Response to Neoadjuvant Chemotherapy Using Core Needle Biopsy Samples with the Prosigna Assay. Clinical Cancer Research. 22(3). 560–566. 64 indexed citations

Gnant, Michael, Ivana Šestak, Martin Filipits, et al.. (2015). Identifying clinically relevant prognostic subgroups of postmenopausal women with node-positive hormone receptor-positive early-stage breast cancer treated with endocrine therapy: a combined analysis of ABCSG-8 and ATAC using the PAM50 risk of recurrence score and intrinsic subtype. Annals of Oncology. 26(8). 1685–1691. 77 indexed citations

Wallden, Brett, James J. Storhoff, Torsten O. Nielsen, et al.. (2015). Development and verification of the PAM50-based Prosigna breast cancer gene signature assay. BMC Medical Genomics. 8(1). 54–54. 337 indexed citations

Lænkholm, Anne‐Vibeke, Maj‐Britt Jensen, Jens Ole Eriksen, et al.. (2015). Prediction of 10yr distant recurrence (DR) using the Prosigna (PAM50) assay in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal Danish women with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET) alone.. Journal of Clinical Oncology. 33(15_suppl). 546–546. 2 indexed citations

10.

Lænkholm, Anne‐Vibeke, Maj‐Britt Jensen, Jens Ole Eriksen, et al.. (2015). Prediction of late distant recurrence (DR) using the Prosigna (PAM50) test in a Danish Breast Cancer Cooperative Group (DBCG) cohort of postmenopausal women diagnosed with hormone receptor-positive (HR+) early breast cancer (EBC) allocated to 5yr of endocrine therapy (ET).. Journal of Clinical Oncology. 33(15_suppl). 544–544. 3 indexed citations

11.

Ribelles, Nuria, Pedro Sánchez‐Rovira, Luís Vicioso, et al.. (2015). Prosigna (PAM50) to predict response to neoadjuvant chemotherapy (NAC) in HR+/HER2- early breast cancer (EBC) patients.. Journal of Clinical Oncology. 33(15_suppl). 11049–11049. 3 indexed citations

12.

Ejlertsen, Bent, Maj‐Britt Jensen, Jens Ole Eriksen, et al.. (2015). Validation of prediction of distant recurrence (DR) by Prosigna (PAM50) in subgroups of a Danish Breast Cancer Cooperative Group (DBCG) cohort of node-positive (N1), hormone receptor positive (HR+), postmenopausal early breast cancer (EBC) patients allocated 5yr of endocrine therapy (ET).. Journal of Clinical Oncology. 33(15_suppl). 513–513. 4 indexed citations

13.

Wallden, Brett, Sean Ferree, Harini Ravi, et al.. (2015). Development of the molecular diagnostic (MDx) DLBCL Lymphoma Subtyping Test (LST) on the nCounter Analysis System.. Journal of Clinical Oncology. 33(15_suppl). 8536–8536. 9 indexed citations

14.

Nielsen, Torsten O., Brett Wallden, Carl Schaper, et al.. (2014). Analytical validation of the PAM50-based Prosigna Breast Cancer Prognostic Gene Signature Assay and nCounter Analysis System using formalin-fixed paraffin-embedded breast tumor specimens. BMC Cancer. 14(1). 177–177. 211 indexed citations

15.

Šestak, Ivana, Jack Cuzick, Mitch Dowsett, et al.. (2014). Prediction of Late Distant Recurrence After 5 Years of Endocrine Treatment: A Combined Analysis of Patients From the Austrian Breast and Colorectal Cancer Study Group 8 and Arimidex, Tamoxifen Alone or in Combination Randomized Trials Using the PAM50 Risk of Recurrence Score. Journal of Clinical Oncology. 33(8). 916–922. 160 indexed citations

16.

Gnant, Michael, Martin Filipits, Peter Dubsky, et al.. (2013). Predicting Risk for Late Metastasis: the PAM50 Risk of Recurrence (ROR) Score After 5 Years of Endocrine Therapy in Postmenopausal Women with Hr+ Early Breast Cancer: a Study On 1,478 Patients from the Abcsg-8 Trial. Annals of Oncology. 24. iii29–iii29. 15 indexed citations

17.

Šestak, Ivana, J. Cuzick, Mitch Dowsett, et al.. (2013). Abstract S6-04: Prediction of late distant recurrence after 5 years of endocrine treatment: A combined analysis of 2485 patients from the ABCSG-8 and transATAC studies using the PAM50 risk of recurrence (ROR) score. Cancer Research. 73(24_Supplement). S6–4. 2 indexed citations

18.

Dowsett, Mitch, Elena López‐Knowles, Kiran Sidhu, et al.. (2011). S4-5: Comparison of PAM50 Risk of Recurrence (ROR) Score with OncotypeDx and IHC4 for Predicting Residual Risk of RFS and Distant-(D)RFS after Endocrine Therapy: A TransATAC Study.. Cancer Research. 71(24_Supplement). S4–5. 8 indexed citations

19.

Gleaves, Curt A., Tarek Elbeik, Valerie L. Ng, et al.. (2002). Multicenter evaluation of the Bayer VERSANT™ HIV-1 RNA 3.0 assay: analytical and clinical performance. Journal of Clinical Virology. 25(2). 205–216. 44 indexed citations

20.

Schaper, Carl, et al.. (1979). Subacute combined degeneration of the spinal cord and the vitamin b12 metabolism. Clinical Neurology and Neurosurgery. 81(1). 26–38. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact